Primary objective:
- To demonstrate that the clinical efficacy of telithromycin (800 mg od for 5 days) is
non-inferior to amoxicillin-clavulanic acid (875/125 mg bid for 10 days) at the
test-of-cure (TOC) visit (Day 17-21) in subjects with acute bacterial sinusitis (ABS).
Secondary objective(s):
- To assess the time to resolution of signs and symptoms between the baseline (Day 1) and
TOC (Day 17-21) visits,
- To assess the rate of clinical relapse at the follow-up visit (Day 41-49),
- To assess health economic outcome until follow-up visit (Day 41-49),
- To assess quality of life up to the follow-up visit (Day 41-49),
- To compare the safety of telithromycin and amoxicillin-clavulanic acid,
- To compare the bacteriologic outcome of both treatments as observed at TOC (Day 17-21)
and at follow-up visit (Day 41-49),in subjects with ABS.